approval
saveRYBREVANT FASPRO (AMIVANTAMAB AND HYALURONIDASE-LPUJ) — FDA approval
community read0 votes
Sponsor: JANSSEN BIOTECH. Form: INJECTION
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 1
same company · ±60 days · 6
- approval(abiraterone acetate + niraparib): AKEEGA (ABIRATERONE ACETATE) — FDA approvalDec 12, 2025
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 19, 2025
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 14, 2025
- approvallazertinib mesylate: LAZCLUZE (LAZERTINIB MESYLATE) — FDA approvalNov 7, 2025
- approvalamivantamab: RYBREVANT (AMIVANTAMAB-VMJW) — FDA approvalNov 7, 2025
- approval(daratumumab + hyaluronidase (human recombinant)): DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approvalNov 6, 2025
comments(0)
5-min edit window · permanent after that